Plain-English translation of NCT06008106 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called to treat advanced melanoma in patients whose cancer has a specific genetic change (NRAS mutation) and who have already tried immunotherapy without success. Two-thirds of participants will take as a daily oral capsule, while one-third will receive standard chemotherapy drugs that your doctor chooses based on what's best for you. The study will compare how well each treatment works and how safe it is.
Many people with this type of melanoma don't respond well to or can't tolerate immunotherapy, leaving them with limited options. This medication is designed to target the specific genetic mutation driving their cancer, and researchers want to see if it works better than traditional chemotherapy for these patients.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to the medication group, you will take capsules by mouth twice daily in 28-day cycles for as long as the treatment is working and you can tolerate it. If you are assigned to the chemotherapy group, you will receive chemotherapy infusions (the specific drug combination will depend on what your doctor thinks is best for you) every 28 days. Throughout the study, you will have regular blood tests, imaging scans, and heart function checks. After your treatment ends, the study team will follow up with you every 12 weeks for up to a year to check how you're doing and to track your survival.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China